Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 4/20 | 0.66 |
| ▸ | NTRK1 | P04629 | 7/20 | 0.48 |
| ▸ | NTRK3 | Q16288 | 5/20 | 0.48 |
| ▸ | NTRK2 | Q16620 | 5/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.44 |
| ▸ | CDK2 | P24941 | 6/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | PRKCB | P05771 | 1/20 | 0.42 |
| ▸ | INSR | P06213 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1370706 | 0.95 | IGF1R (0.74) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL1372749 | 0.93 | IGF1R (0.62) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL1891938 | 0.90 | IGF1R (0.70) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL1373530 | 0.90 | IGF1R (0.70) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL1373097 | 0.89 | IGF1R (0.55) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL1371979 | 0.87 | IGF1R (0.63) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL4291339 | 0.87 | IGF1R (0.55) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL4291336 | 0.86 | IGF1R (0.54) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL4285322 | 0.86 | IGF1R (0.64) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL1371524 | 0.86 | IGF1R (0.58) | IGF1RNTRK1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288088-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.I. (IT) | 2011-11-24 | — | — | US | disclosed |
| US-7968583-B2 | Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288088-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K5, MAP3K19, MAP3K3 | IGF1R 737/4885NTRK1 1363/4885NTRK3 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.